Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Market Size (2023 to 2028)

The global erectile dysfunction drugs market size is estimated to be valued at USD 4571 million by 2028 from USD 3561 million in 2023, growing at a CAGR of 5.12% from 2023 to 2028.

Erectile Dysfunction (ED) also called impotence is a medical condition in which a male faces difficulty in achieving an erection or maintaining it during sexual activity. It may also include reduced firmness of erections. Various causes lead to this condition, ranging from physical conditions like diabetes, heart diseases, and nerve damage to psychological conditions including stress, anxiety, and depression. Therefore, the global ED drug market consists of multiple treatment options including medications (called PDE5 inhibitors), psychotherapy, and lifestyle changes. Other treatment options include testosterone replacement therapy, penile injections, vacuum pumps, and surgery.

Impact of COVID-19 on the global erectile dysfunction drugs market:

The COVID-19 pandemic has shown positive and negative impacts on the global erectile dysfunction drugs market. Many governments have taken measures such as lockdowns, bans on traveling and temporary shutdowns of businesses to limit the spread of coronavirus among people and this has resulted in the reduced demand for non-essential medications, including erectile dysfunction drugs. The COVID-19 pandemic has caused disruptions in the supply chain, manufacturing and distribution of pharmaceutical products worldwide and affected the availability of erectile dysfunction drugs in several regions and impacted the market growth negatively. On the other hand, the COVID-19 pandemic also affected the psychological well-being of individuals, leading to increased levels of stress, anxiety, and depression, which are the contributing factors to erectile dysfunction. There have been reports of increased demand for erectile dysfunction drugs during the pandemic, as people spent more time at home and were involved in sexual activity. Likewise, the global erectile dysfunction drugs market has experienced a mixed impact from the COVID-19 pandemic. However, the market is expected to recover and post a healthy CAGR during the forecast period.

MARKET DRIVERS:

The increasing number of cases of erectile dysfunction worldwide is one of the major factors driving the growth of the global erectile dysfunction drugs market. The prevalence of ED is rising due to the adoption of unhealthy and sedentary lifestyles with no physical activity and the rising number of physiological diseases including diabetes, cardiovascular disease, hormonal imbalances, obesity and blood pressure. Due to hectic work schedules, there are increased cases of depression and emotional imbalance which also fuel the number of ED cases. Moreover, the habits of consuming ready-to-eat food items, fast food, drinking alcohol, and smoking also contribute to the rising number of cases that drive the market growth. According to research by The Journal of Sexual Medicine, ED is less common but increasing in young men. Previously, only 5% to 10% of men younger than 40 experienced ED, however, the percentage has increased over time to around 28%.

The growing geriatric population worldwide further contributes to the global erectile dysfunction drugs market growth. The aging population is more prone to ED due to the prevalence of age-related physiological changes in the body, including chronic diseases and testosterone levels. According to a 2019 study by the University of Wisconsin Health, ED affects about 10% of men per decade of life. For example, 50% of men in their 50s suffer from some form of erectile dysfunction. Also, men older than 40 are three times more likely to experience ED than younger men.

The growing awareness among people regarding the availability of treatment for erectile dysfunction fuels the market's growth rate. As people in emerging countries become more open about their sexual problems, there is an increased demand for diagnosis and medical treatment of ED among people. The growing concern about maintaining health and increased spending on healthcare particularly in emerging nations, is expected to boost the ED drugs market. The growing investments in R&D by the key market players for the development of new and advanced treatment options for erectile dysfunction also drive market growth. Currently, the recent developments in the ED market include vacuum erection devices, penile injections, and surgery, which will drive market growth in the future as more people continue to adopt these options.

MARKET RESTRAINTS:

Lack of awareness among people in low and middle-income countries regarding erectile dysfunction majorly hampers market growth. The lower purchasing power of these people can affect their willingness to seek treatment for the issue and incorporate it into their daily life. Moreover, men might feel embarrassed in seeking treatment for ED as it is a sensitive topic. The stigma associated can result in lower rates of diagnosis. The side effects associated with the usage of ED drugs, including headache, nasal congestion, dizziness, diarrhea and others are another notable factor limiting the adoption of these drugs and hindering the market growth. These side effects discourage people from seeking treatment or they stop taking medicines before the prescribed course is completed. In developing countries, there is increasing availability of fake or counterfeit products which are marketed at a lower price compared to original or patented ED medications. These counterfeit medicines can affect the patient negatively, leading to the loss of trust in legitimate ED treatments. Such factors are further inhibiting the market's growth rate.

REPORT COVERAGE:

This research report on the global erectile dysfunction drugs market has been segmented and sub-segmented based on the Product, Mode of Administration, Distribution Channel & Region

Erectile Dysfunction Drugs Market – By Product:

• Viagra (sildenafil citrate)
• Cialis (Tadalafil)
• Levitra/Staxyn (vardenafil)
• Stendra/Spedra (avanafil)
• Zydena (udenafil)
• Vitaros (Alprostadil Cream)

Based on the product, the Viagra segment held the major share of the global market in 2022 and the segmental domination is anticipated to continue throughout the forecast period. This drug helps in the treatment of ED by increasing the blood flow to the penis. The drug has been proven effective as at least two-thirds of men reported improvement in their erections. Thus, the effectiveness of sildenafil citrate sold under the brand name Viagra in the treatment of erectile dysfunction is expected to boost the growth of the segment over the forecast period.

Erectile Dysfunction Drugs Market – By Mode of Administration:

• Oral Medications
• Topical Medications
• Injections

Based on the mode of administration, the oral segment accounted for the largest share of the global market in 2022 and will continue to do so during the forecast period. The oral administration method is chosen over the many alternative drug delivery administration routes due to its numerous advantages. Safety, good patient compliance, ease of intake, pain prevention and versatility to handle various medications are just a few of the benefits.

Erectile Dysfunction Drugs Market – By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel, the retail pharmacies segment held the largest share of the global ED drugs market in 2022. Easy access to medicines and the availability of generic ED drugs via retail pharmacies majorly drive segmental growth.

The hospital segment accounted for the second-largest share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. Patients in developed countries majorly prefer prescribed drugs from hospital pharmacies, which is primarily contributing to segmental growth.

The online pharmacies segment is predicted to gain momentum and register a healthy growth rate during the forecast period. Online portals also play a major role in delivering erectile dysfunction drugs to patients. Easy access to medications and decreased social stigma regarding sexual dysfunctions are major factors contributing to segmental growth. The accessibility of online portals by pharmaceutical companies such as Pfizer and Cipla provides ED drugs through online channels.

Erectile Dysfunction Drugs Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America accounted for the largest share of the global market in 2022 and is expected to continue to be the leading region in the worldwide market throughout the forecast period. The growing aging population and increasing incidence of erectile dysfunction among the North American population primarily propel the North American market growth. As per the data published by the U.S. Census Bureau, the number of males aged between 60 to 65 years in the U.S. reached 9.9 million in 2020. Because ED is ubiquitous in men over 42, the rise in the geriatric male population is predicted to increase the number of individuals suffering from it. The growing availability of various ED drugs through over-the-counter (OTC) and online channels and the presence of improved healthcare infrastructure in North America further contribute to the regional market growth. The U.S. led the erectile dysfunction market in North America in 2022 and is expected to hold the dominating position in the North American region throughout the forecast period. The highest self-reported ED is seen in the United States and this growing prevalence of ED is anticipated to fuel the U.S. market growth throughout the forecast period. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021 report, around 30 million men suffer from erectile dysfunction in the United States.

The European market for erectile dysfunction drugs is predicted to grow at a promising CAGR during the forecast period due to the review of regulatory bodies on erectile dysfunction drugs. The growing geriatric population in the European region and an increasing number of drug launches by market participants in Europe further boost the growth rate of the European market.

The Asia Pacific market is predicted to register the highest CAGR in the worldwide market during the forecast period. The growing patient count suffering from erectile dysfunction in the Asia-Pacific region primarily boosts regional market growth.

Although the markets in the Middle East, Africa, and Latin America are still in their infant stage, increased awareness about the condition and treatment in these regions is likely to contribute to considerable growth in the market during the forecast period.

KEY MARKET PARTICIPANTS:

Companies playing a notable role in the global membrane chromatography market profiled in this report are Bayer AG, Apricus Biosciences, Meda Pharmaceuticals, Dong-A Pharmaceutical, Pfizer, Eli Lilly and Company, Vivus, Cristalia Produtos Quimicos Farmaceuticos, Dong-A Socio, and Endo Pharmaceuticals.

RECENT MARKET DEVELOPMENTS:

• In April 2023, UK R&D firm Futura launched in its home market its drug-free erectile dysfunction gel under the Eroxon brand, marketed by France's Cooper Consumer Health. European consumers can now buy Futura Medical's Eroxon erectile dysfunction gel without a prescription online, and in person via Belgian pharmacies.
• In March 2023, Researchers in Australia claim to have developed a nasal spray to combat erectile dysfunction — and it could be rolled out to American consumers within two years. The spray-to-play product could be a bedroom game changer for the 30 million Americans who struggle to gain and maintain an erection as it goes straight into the bloodstream and has an effect in 5 to 15 minutes.
• In August 2022, Lupin launched an oral drug called sildenafil for the treatment of ED in the United States
• Glenmark Pharma received final approval from the U.S. Food and Drug Administration in December 2020 for Tadalafil tablets used to treat erectile dysfunction and enlarged prostate.
• Launch Medical and GAINS Wave announced the settlement of their case in June 2020, and they began working together to sell The Phoenix, a new home-use acoustic wave device for the treatment of erectile dysfunction.
• Pfizer Upjohn, a division of Pfizer Biopharmaceuticals Company, started a campaign called #KeepItReal on August 31, 2019.